{"date":"2025-05-30","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6576-2025-05-30-1538-1hac0ne","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2025-05-30","time":"15:38:03","subject":"本公司授權夥伴Accord Healthcare向英國藥品及健康產品管理局（MHRA）提交前列腺癌新劑型新藥 CAMCEVI 3個月劑型新藥上市申請","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2025-05-30 15:38，「本公司授權夥伴Accord Healthcare向英國藥品及健康產品管理局（MHRA）提交前列腺癌新劑型新藥 CAMCE」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}